File No: BIO/Form44/FF/2018/6570
Directorate General of Health Services
Central Drugs Standard Control Organization
FDA Bhawan, Kotla Road New Delhi - 110002
(Biological Division)

Dated: 22-MAY-2018

To

M/s. Serum Institute Of India Pvt. Ltd.,
212/2, Off. Soli Poonawalla Road Hadapsar,
Pune Maharashtra (India) – 411028.

Subject: Permission for Phase II/III clinical trial titled " A Phase-II/III, Partially Double-blind, Randomized, Active-controlled, Multicentric Study to Assess the immunogenicity and Safety of SIIPL's qHPV Vaccine Administered Intramuscularly in Healthy Volunteers according to a Two-dose Schedule to Cohort 1 (Girls and Boys Aged 9-14 years) and a Three-dose Schedule to Cohort 2 (Women and Men Aged 15-26 years) as Compared to Merck's HPV6/11/16/18 vaccine (Gardasil®)".

CT No. CT- 10/2018

Reference: Your Application No. BIO/Form44/FF/2018/6570 dated 16-01-2018 on the subject mentioned above.

Sir,

This Directorate has no objection to your conducting the subject mentioned clinical trial as per the provisions of Drugs and Cosmetics Rules under the supervision of the following investigators mentioned in your letter and as per **Protocol No.: SII-qHPV/IN-02, Version No. 2.0, Date 24-04-2018** submitted to this Directorate.

1. Dr. Neerja Bhatla, All India Institute of Medical Sciences, Department of Obstetrics & Gynaecology,3rd Floor, Room No. 3101, Teaching Block Ansari Nagar,South Delhi-110029, India.
2. Dr. AnandShantharam Kawade, King Edward Memorial Hospital Research Centre, KEM Hospital Pune, Ankit Shirdi Sai Baba Rural Hospital, A/P- Vadu Budruk, Taluka- Shirpur, District,Pune-412216, India.
3. Dr. Nene Bhagwan Mahadeo, Nargis Dutt Memorial Cancer Hospital, Agalgaon Road, Barshi 413401 Maharashtra, India.
4. Dr. Chetna Maliye, Department of Community Medicine, Dr. Sushila Nayar School of Public Health, Mahatma Gandhi Institute of Medical Sciences, Sewagram-442102, Wardha (Maharashtra), India.
5. Dr. Dipanwita Banerjee, Chittaranjan National Cancer Institute, Department of Gynaecology & Oncology, Room No. 124, 1st Floor, Hospital wing, 37, S P Mukherjee road, 700026, Kolkata, India.
6. Dr. Latha Balasubramani, G. Kappuswami Naidu Memorial Hospital, No. 6327, Nethaji Road, Pappanaickenpalayam, Coimbatore, Tamil Nadu 641037, India.
7. Dr. Abraham Peedicayil, Christian Medical College, Ida Scudder Road,Vellore – 632004, Tamil Nadu, India.
8. Dr. Rajini Uday, M. S. Ramaiah Medical College and Hospital, M S Ramaiah Nagar, Mathikere, MSRIT Post, Bengaluru, Karnataka 560054, India.
9. Dr. Sanjay Lalwani, Bharati Vidyapeeth Deemed University Medical College and Hospital, Department of Pediatrics, Pune - Satara road, Dhanakwadi, Katraj, Pune 411043, India.
10. Dr. Sharmila Pimple, Tata Memorial Hospital & Cancer Research Institute, Department of Preventive Oncology, Dr Ernest Borges Marg-400 012 Mumbai, Maharashtra, India.
11. Dr. Smita N. Joshi, Jehangir Clinical Development Centre Pvt. Ltd 32, Sassoon Road, Pune-411001, Maharashtra, India.
12. Dr. Usha Rani Poli, MNJ Institute Of Oncology & Regional Cancer Centre, Red Hills, Lakdikapul, Hyderabad, India-500004, India.
13. Dr. Vanita Suri, Post Graduate Institute of Medical Education and Research, Department of Gynaecology and Obstretics, Sector 12,Chandigarh-160012, India, India.
14. Dr. Veena Kamath, Kasturba Medical College, Madhav Nagar, Near Tiger Circle, Manipal, Karnataka 576104, India.

The clinical trial permission is subject to the following conditions:

a) Clinical trial shall be conducted in compliance with the approved protocols, requirements of Schedule Y, Good Clinical Practice Guidelines issued by this Directorate and other applicable regulations.
b) Approval of the Ethics Committee duly registered with the office of DCG (I) shall be obtained before initiating the clinical trial.
c) Clinical trials shall be registered at Clinical trials Registry of India before enrolling the first patient for the study.
d) Annual status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Licensing Authority, and in case of termination of any clinical trial the detailed reasons for the same shall be communicated to the said Licensing Authority.

e) Any report of serious adverse event occurring during clinical trial study to the subject, after due analysis, shall be forwarded within fourteen days of its occurrence as per Appendix XI and in compliance with the procedures prescribed in Schedule Y.

f) In case of an injury or death during the study to the subjects, the applicant shall provide complete medical management and compensation in the case of trial related injury or death in accordance with rule 122 DAB and the procedures prescribed under Schedule Y, and the details of compensation provided in such cases shall be intimated to the Licensing Authority within thirty days of the receipt of the order of the said authority.

g) The premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial study sites shall be open to inspection by the officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to verify compliance to the requirements of Schedule Y, Good Clinical Practices guidelines for conduct of clinical trial in India and other applicable regulations.

h) The Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial study sites and the Investigator shall allow officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to enter with or without prior notice, any premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial sites to inspect, search and seize any record, data, document, books, investigational drugs, etc. related to clinical trial and provide adequate replies to any queries raised by the inspecting authority in relation to the conduct of clinical trial.

i) Clinical trial shall be conducted only at those sites which are institutes/hospitals having adequate emergency facilities and duly registered Institutional Ethics committees.

j) The details of payment/honorarium/financial support/fees paid by the Sponsor to the investigator (s) for conducting the study shall be made available to this Directorate before initiation of each of the trial sites.

k) An audio - video recording of the informed consent process in case of vulnerable subjects in clinical trials of New Chemical Entity or New Molecular Entity including procedure of providing information to the subject and his understanding on such consent, shall be maintained by the investigator for record; Provided that in case of clinical trial of anti-HIV and anti-Leprosy drugs, only audio recording of the informed consent process of individual subject including the procedure of providing information to the subject and his understanding on such consent shall be maintained by the investigator for record.

l) It may kindly be noted that merely granting permission to conduct clinical trials with the drug does not convey or imply that based on the clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.

m) **The formulation intended to be used in the clinical trial shall be manufactured under GMP conditions using validated procedures and shall have ongoing stability programme.**

n) **Only CDL, Kasauli certified batches shall be used in the clinical trial.**

Yours faithfully,

S ESWARA REDDY

Digitally signed by S ESWARA REDDY
Date: 2018.06.07 13:00:39 +05'30'

(Dr. S. Eswara Reddy)
Drugs Controller General (India)